Volkmar Mueller, MD, reviews recent data from the HER2CLIMB trial and discusses the recent regulatory approval in Europe for patients with HER2+ breast cancer.
Exciting Approval in Europe for HER2-Positive Breast Cancer
Experts in breast oncology review the favorable safety profile of tucatinib for patients with metastatic HER2+ breast cancer.
An examination of the real-world data supporting the use of tucatinib for patients with metastatic HER2+ breast cancer in Europe.
Experts discuss the clinical implications of the approval of tucatinib in Europe, specifically for patients with active brain metastases.
Volkmar Mueller, MD, shares insight on the potential sequencing of available therapeutics for patients with metastatic HER2+ breast cancer.
Considerations on the evolving landscape and ongoing unmet needs for patients with HER2+ breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5